Research Fellow in Cell Biology
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Dept of Medicine, Division of Genetics
330 Brookline Ave
Boston MA 02215
|Institute of Oncology Research (IOR), Faculty of Biology and Medicine, University of Lausanne, Bellinzona, Switzerland
|Second Military Medical University, Shanghai, China
|East China University of Science and Technology, Shanghai, China
Pfizer Research Award in Oncology, Pfizer Research Prize Foundation
Prix de la Faculté de biologie et de médecine, University of Lausanne
2019 - 2020
Early Postdoc.Mobility Fellowship, Swiss National Science Foundation
Award of the Best Publication, the 8th Giornata della Ricerca della Svizzera Italiana
IBSA Foundation Fellowship Award for Scientific Research, IBSA Foundation
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
to make corrections and additions.
Feb 1, 2019 - Aug 31, 2020
Swiss National Science Foundation
Tumour Derived Vaccine Adjuvants for Advanced Cancers
Role Description: The overall goal of the project is to develop a novel approach of tumour derived vaccine adjuvants for cancer immunotherapy. The proposal leverages on the key findings on the involvement of the nucleic acids including noncoding RNA in innate immunity and the facts that chemical synthesized, or bacterial nucleic acid vaccine adjuvants elicited striking tumor suppression. These discoveries shed the light that aberrantly expressed non-coding RNA initiated upon chromosome damage due to the replicative stress during the cancer progression or genotoxic agent treatment could potentially trigger cancer cell-autonomous innate immunity for anti-cancer therapy. This proposal will take advantage of CRISPR activation screen platform, etc to investigate whether boosting the expression of tumour derived non-coding RNAs striving in genomic integrity maintenance in advanced cancers will make cancer cells self-exposed to or ‘visualized’ by innate immune surveillance and this novel noncoding RNA adjuvant may represent a breakthrough for the therapeutic vaccination against cancer.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.